SEGRON Announces New Funding Round to Expand Into Industries Building Back From COVID-19 and Accelerating Digital Transformation
7.4.2021 08:00:00 EEST | Business Wire | Press release
SEGRON, a leader in the next generation of active testing, today announces the completion of a new round of funding, bringing total capital raised to-date up to $10million. The funding round, led by OTB Ventures and Credo, comes amid significant momentum for the business, having achieved a leadership position in automation services for the telecoms industry. Proceeds from the raise will be used to fund international growth and expand into new industry verticals that are seeing a resurgence of demand and accelerated digital adoption as a result of the progression of the Covid-19 pandemic.
International scale to capture a $35bn market opportunity
SEGRON offers automated solutions to test new digital services in any location, with any device, anytime. SEGRON’s leadership position in test automation solutions for the telecoms ecosystem enables operators including Telefonica, T-Mobile Group and Swisscom to ensure optimal service quality for end-subscribers while enabling faster go-to-market for next-generation 5G and IoT services.
SEGRON’s success with telecoms operators in the European Union is now attracting attention from a wide array of international players in the global telecoms market. With Covid-19 increasing demand for telecoms services SEGRON has become an attractive partner for telecoms operators facing increased pressures to roll out next-generation networks at pace. This includes expansion into North America with a new agreement with a Canadian telecoms operator. In the year ahead, SEGRON is expecting to expand its global presence further to Middle East and Africa and the Asia-Pacific region.
Expanding from telecoms industry to e-commerce, automotive and consumer electronics
Automated testing also enables businesses undergoing rapid digital transformation to accommodate the growing list of testing requirements to ensure a high-performing user experience. SEGRON’s leadership in the telecoms industry has built momentum to expand into e-commerce, automotive and consumer electronics, with the first major OEM announced in the consumer electronics industry today as global handset manufacturer. The advanced AI based testing automation solution helps to keep pace with the mobile devices evolution, ensuring day 1 availability even with pre-released devices for testing automation.
Today’s new funding enables SEGRON to further expand into these adjacent industries and deploy automated testing solutions to enhance the end user experience while shortening the time-to-market for new products and services. In the next few years, the Company will focus on AI and anticipates the launch of a new product, Global Service Enabler in April 2021 which helps verify the performance of digital services over international and roaming networks from any location.
With the market dynamics in telecoms and new industry verticals, SEGRON anticipates growing by over 300% in the year ahead to achieve annual recurring revenues in excess of $5m on a run-rate basis.
According to Global Market Insights, the automation testing market is expected to grow at 15% CAGR between 2020 and 2026, reaching an estimated global market value of $35bn.
Hiring new talents for accelerated growth
In conjunction with today’s new funding round, SEGRON also announces the appointment of three new executives to the senior management team - Jean-Philippe Leloup joins as Deputy Chief Executive Officer, Rita D’Agostino joins as Chief Marketing Officer and Martin Hochmeister joins as Chief Revenue Officer.
Martin Hochmeister joined with leadership experience in technology business environments, most recently with automation business Scanpoint GMBH where he ran sales and marketing as the business scaled-up its growth within Europe. Rita D’Agostino joined SEGRON with international experience in digital marketing and big data. Rita’s background is in the automotive industry, with a career spanning Fiat Chrysler Automobiles, Kia Corporation and Maserati.
Jean-Philippe Leloup joined SEGRON from IDI Group LLC, an investor in early stage companies playing an active role in business development and value creation. Similar to Rita D’Agostino, Jean-Philippe previously worked in the automotive industry, leading Ferrari's business operations in central and eastern Europe before building Maserati Commercial as a new division within the Italian automaker.
Wireless connectivity in the automotive industry makes SEGRON a highly compelling partner for automotive OEMs looking to adopt technologies ranging from automated robotic assembly lines to self-driving cars. The vast bandwidth and low latency of wireless communication between devices and control systems require continuous and fully automated testing, creating a new market opportunity for SEGRON’s automation solutions.
As SEGRON looks to expand its industrial scale in new industries and international markets, it is anticipated that its workforce will increase by 30% by the end of 2021.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005984/en/
Contact information
Rob Mindell / Valerija Cymbal
FTI Consulting
T: +44 20 3727 1000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
